| Course | NU675 PMHNP Diagnosis and Management Across the Lifespan II |
|---|---|
| Unit | Unit 1 |
| Paper type | Discussion board post with two replies |
| Length | About 480 words, 2 pages double-spaced |
| Format | APA 7 discussion post |
| School | Purdue University Global |
| Program | MSN |
| Updated | September 2026 |
Free sample paper for NU675 Unit 1
Nine Months Well on Vortioxetine: Does Remission Ever Make Stopping the Sounder Plan After a First Episode?
NU675 · Unit 1 Discussion Board Post
Posted by [Student Name]
The patient is composite; details are bracketed.
Initial Post
Ms. [H.] is a [34]-year-old freelance translator who had her first major depressive episode two years ago, after a difficult move and a breakup. She responded to vortioxetine [10] mg and has been in full remission, PHQ-9 below [5], for nine months. She asks: "Do I have to take this forever?"
The evidence on continuing antidepressants is strong in one direction. A meta-analysis of relapse prevention trials found that continuing an antidepressant roughly halved the risk of relapse compared with switching to placebo, with the benefit holding across drugs and durations studied (Geddes et al., 2003). More recently, the ANTLER trial randomized primary care patients who felt well enough to consider stopping, all of whom had at least two previous episodes or two or more years on treatment, to continue or taper their antidepressant. By one year, [56] percent of those who stopped had relapsed compared with [39] percent of those who continued (Lewis et al., 2021).
So why would stopping ever be sounder? Because the risk is not the same for everyone. The ANTLER patients all had recurrent depression or long treatment; a first episode in full remission after an adequate continuation period is a different starting point. Ms. [H.]'s case has several features that favor a trial off medication: one episode, a clear precipitating stress that has resolved, full remission for nine months, good supports and early warning signs she can recognize.
My position: for her, a gradual taper over several months, with monthly PHQ-9 checks for a year and a written plan to restart promptly if early signs return, is reasonable, and so is continuing. The decision should be hers, made with the numbers in front of her. If she had had two or more episodes, or residual symptoms, I would recommend continuing.
What factors would change your recommendation for her?
Reply to a Classmate Who Would Always Continue
You pointed to ANTLER and said stopping is simply riskier. I agree the trial is persuasive, and I would share its numbers with her. But ANTLER enrolled only people with at least two previous episodes or two or more years of treatment, so its finding may overstate the risk for a first episode after nine months (Lewis et al., 2021). Continuing is the safer default; it does not have to be the only option.
Reply to a Classmate Who Asked About Withdrawal
You asked whether vortioxetine causes withdrawal symptoms. The ANTLER discontinuation group reported more withdrawal symptoms as well as more depression (Lewis et al., 2021), which is one reason a slow taper and close follow-up matter. Distinguishing early withdrawal from early relapse is part of the plan.
References
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003). Relapse prevention with antidepressant drug treatment in depressive disorders: A systematic review. The Lancet, 361(9358), 653-661. https://doi.org/10.1016/S0140-6736(03)12599-8
Lewis, G., Marston, L., Duffy, L., Freemantle, N., Gilbody, S., Hunter, R., Kendrick, T., Kessler, D., Mangin, D., King, M., Lanham, P., Moore, M., Nazareth, I., Wiles, N., Bacon, F., Bird, M., Brabyn, S., Burns, A., Clarke, C. S., . . . Lewis, G. (2021). Maintenance or discontinuation of antidepressants in primary care. New England Journal of Medicine, 385(14), 1257-1267. https://doi.org/10.1056/NEJMoa2106356
NU675 Unit 1 instructions, in plain terms
The opening NU675 discussion puts a long-term management question to you and wants a stated position and defend it with evidence. Prompts often present a patient who is well on medication and ask whether stopping is ever the better plan. Most instructors want a first post near 450 words and two shorter replies, and every one of them should cite something. Instructors look for a position that is specific to the patient rather than a blanket rule, and for honest use of evidence that may point the other way. Naming the factors that would change your recommendation, such as the number of prior episodes or residual symptoms, shows that the position has limits and that you know where they are.
How this NU675 Unit 1 example is built
The post introduces the patient, her single episode and her question in her words. The next paragraph summarizes the two main sources: the Geddes meta-analysis of relapse prevention trials and the ANTLER results at one year, 56 percent relapse after stopping against 39 percent with continued treatment. A highlighted sentence then explains why her situation differs from the trial population. Her favorable features are listed, and the position follows with a taper, monthly PHQ-9 checks and a plan to restart. A closing question asks classmates what would change the recommendation. Of the two replies, one takes on a classmate who would never stop, and the other addresses withdrawal symptoms during a taper and how they differ from relapse.
Where the points sit in the NU675 Unit 1 rubric
On this post, marks follow five things: how clearly the stance is put, the quality of the evidence, how well the evidence is applied to the patient, peer engagement and writing. The position earns full marks when it is stated plainly with its conditions. Evidence points reward recent trials and systematic reviews described accurately, including who was enrolled. Application is judged on whether the post explains how the patient differs from, or resembles, the studied population. Engagement credit depends on replies that answer a classmate's specific argument with a reason or a source. Writing covers APA citations, a logical order and keeping within the length the instructor sets for the post and replies.
NU675 Unit 1 help: mistakes that cost points
A common mistake is quoting a large trial's relapse rate as if it applied to every patient, without checking who was enrolled. Another is taking an absolute position, always continue or always stop, which ignores the factors that change the risk. Students often forget withdrawal symptoms, which can be mistaken for relapse during a taper. Some posts leave out the patient's own wishes, which should shape the decision when two options are both reasonable. Others propose stopping without a monitoring plan or a clear rule for restarting. And replies that repeat the original post, or simply agree, add nothing to the discussion and earn little credit.
Get an NU675 Unit 1 example written to your instructions
Paste the NU675 Unit 1 prompt, noting whether it hands you a patient or asks you to choose one, and include the rubric. Built on those instructions, a first custom post comes free within 24-48h, offering a position on stopping, the counterevidence weighed honestly, and conditions a reader could check later. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
More NU675 papers and MSN samples
- NU675 Unit 2: Continuation Decision Paper
- NU675 Unit 3: Medication Switch Plan
- NU675 Unit 4: Polypharmacy Review
- NU675 Unit 5: Seminar Reflection
- NU675 Unit 6: Relapse Prevention Plan
- NU675 Unit 7: Metabolic Monitoring Brief
- NU675 Unit 8: Discontinuation Case Analysis
- NU675 Unit 9: Recovery Goals Statement
- NU675 Unit 10: Year-long Case Review
- NU674 Unit 1: Outpatient Clinic Learning Objectives
- NU673 Unit 1: Medical Causes Before Anxiety Post
- NU672 Unit 1: Psychotherapy Practicum Learning Goals
- MN501 Unit 1: Discussion Board Post
NU675 Unit 1 questions, answered
How long after remission should a first-episode patient continue treatment?
Guidelines commonly describe a continuation period of roughly six to nine months after remission before stopping is considered, with longer treatment when relapse risk is higher. Cite the guideline you use and its year. The stronger posts then tie the number to the person: the severity of the episode, residual symptoms and stressors ahead can all argue for waiting longer.
Does the post have to discuss discontinuation symptoms?
Briefly, yes, because a taper plan that ignores them leaves a gap. Note that stopping some antidepressants can produce physical and emotional symptoms, that a gradual reduction lowers that risk, and that the plan will distinguish them from a return of depression. Keep the detail proportionate; a long paragraph on withdrawal can crowd out the continuation argument itself.
Can the post disagree with the patient's wish to stop?
It can, if the history supports continuing. Say why, respectfully, and describe what would make stopping reasonable later, such as a longer remission or a change in stressors. A post that simply overrules the patient reads poorly; one that explains the risk and leaves a path open shows the shared decision-making the course expects.
Where can I find a free NU675 Unit 1 sample paper?
This page holds the full NU675 Unit 1 discussion board post and its two replies, with the ANTLER and relapse prevention evidence, the conditional position and the taper plan, plus two references. A post on your own maintenance question can be drafted on request.
What did the ANTLER trial find in NU675 Unit 1?
Among primary care patients with recurrent depression or two or more years of treatment who felt ready to stop, 56 percent of those who tapered off relapsed within a year, compared with 39 percent of those who continued their antidepressant.